CLOSED

GET A PIECE OF PHERDAL FERTILITY SCIENCE, INC.

Building families through science

We believe PherDal is the only sterile, patent-pending, at-home insemination kit out there. Our goal is to provide access to safe and affordable fertility options backed by science. While we are pre-revenue, we have established the trademark for “Pherdal” and our proof-of-concept kits sold out in just 90 days and helped others conceive. We anticipate having a product on the market by the end of 2022.

Show more

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Company Image

$623,150.61 Raised

TEAM

Dr. Jennifer Hintzsche, Ph.D.

Dr. Jennifer Hintzsche, Ph.D. • Chief Executive Officer

Dr. Jenn is a wife, mother, innovator, and passionate advocate for women’s health. Hintzsche was Northern Illinois University’s first recipient of a doctoral degree in bioinformatics (a field of study that combines computer science and biology) in 2014 after obtaining a Master's Degree in the same subject. She earned her BA in Biochemistry from Augustana College. She is the author of over two-dozen peer-reviewed scientific articles and her work has been cited nearly 500 times in respected science journals for her clinical expertise.

Dr. Jenn was diagnosed with unexplained infertility in 2017 and was told expensive fertility options were her only chance at conceiving. Hintzsche and husband Ryan invented and conceived their daughter using their patent-pending PherDal kit. PherDal is the only sterile at-home insemination kit that has already helped over a dozen women conceive. PherDal is located in Dixon, IL and is registered with the FDA as an over the counter medical device.  

Read More

Dr. Karla Loken DO OBGYN FACOOG

Dr. Karla Loken DO OBGYN FACOOG • Advisor

It is an exciting time to be a physician in Industry. I am always learning, and cherish the opportunity to collaborate with talented people in all areas of medical affairs, regulatory, research, and medical education, making a global impact on women’s health! I of course miss and always will miss the privilege to be 1:1 with patients. I was so lucky to have opportunities and experiences as an OB/GYN in private practice /MIS, in academics, and as a hospitalist. 

Experienced in:

Medical Device Development and Strategy, Marketing and VOC

FDA and EU MDA experience in CER, CEP and PFCP and COPA 

Medical Affairs, Regulatory, Payors , Pharmacovigilance, Medical Education, Device Proctoring, and Medical Marketing and HEOR, PMRP, Good Clinical Practice. Clinical Trail Oversight and Onboarding as well as protocol development. VEEVA, Medra, AGILE, Scrum, and Oracle & Teams experience. Individual career transition coaching. Cross-functional team player. Consulting on non-clinical career transition for physicians. Patient Journey, Payer Ad Board Development. Evidence Generation, GCP, Clinical Research Oversight, Onboarding, and Protocol development. ACOOG gov affairs committee -post. PESC- Graduate Education Review committee - post. Girls Experiencing Medical Science mentor ( Gems) girl-scout camp.

Read More

Dr. Steven R. Lindheim, M.D., M.M.M.

Dr. Steven R. Lindheim, M.D., M.M.M. • Medical Advisor

Dr. Lindheim is a Professor of Obstetrics and Gynecology at both Wright State University, Boonshoft School of Medicine in Dayton, Ohio and the University of Central Florida in Orlando, Florida, as well as Visiting Professor of Shanghai Jiao Tong University School of Medicine in Shanghai, China. He graduated from Temple School of Medicine and was a resident at Pennsylvania Hospital in Philadelphia. Dr. Lindheim completed a fellowship in Reproductive Endocrinology and Infertility at the University of Southern California, his Masters in Medical Management from Tulane University, School of Public Health and Tropical Medicine, and is currently Board Certified in both Ob/Gyn and Reproductive Endocrinology and Infertility. He previously served on as the Board of Directors for ASRM and is Past President for the Society of Reproductive Surgeons. Dr. Lindheim has a major interest in In vitro fertilization, oocyte donation, embryo donation and surrogacy. He is a well-recognized expert in the field of minimally invasive reproductive surgery and has over 250 scientific publications, and book chapters and is Associate Editor for Fertility Sterility. His research focuses upon embryo implantation, minimally invasive reproductive surgery, and Polycystic Ovarian Syndrome (PCOS). 

Read More

Reasons to Invest


  • Developing the first FDA-cleared, sterile, patent-pending, assisted reproduction kit as an affordable, over-the-counter fertility option.

  • The Fertility Treatment Market size is valued at $14.27 billion in 2020 and is expected to reach $21.7 billion by 2025 (source).

  • Invented & led by Northern Illinois University’s first recipient of a doctoral degree in bioinformatics, whose clinical research has been cited over 500 times by peers, and was most recently Director of Product for a 15M+ revenue SaaS company. 



(source, source, source, source, source, source, source)






Overview


Empowering people to take control of their fertility journey


Here at PherDal, we aim to provide a science-based, safe, sterile, and affordable fertility option - all in the privacy of your own home. 


(source, source, source, source, source)



In addition to making the fertility journey less invasive, we feel we are a source of support for the LGBTQAI+ community, single parents by choice, and people struggling with infertility. With that, we believe Pherdal offers the only patent-pending, sterile, at-home intracervical insemination kit.  


Founded by a couple who has experienced infertility themselves - our company genuinely understands the hurt, frustration, and pain of trying to conceive. After Dr. Jenn and her husband created PherDal, they conceived their first child in the second month of use. It gave them hope that they could help others as well. 




The Problem


1 in 5 women have difficulty conceiving after one year of trying


An additional 1 in 4 have difficulty carrying a pregnancy to term (source). On top of that, many people also struggle to even afford the services fertility clinics offer (source). The need for assisted reproduction technology is growing at a rate of 5-10% per year to meet the demand of increased infertility (source). We think people need access to safe, sterile fertility options to try in the privacy of their own homes - especially before trying more invasive measures.


(source, source, source, source, source, source, source, source)


Intrauterine Insemination, or IUI, is often the first line of fertility treatment and is performed in a sterile environment at a fertility clinic (source, source).  However, there is a lesser-known form of artificial insemination called Intracervical Insemination or ICI that can be a great first-line of fertility treatment too (source).  A 2015 study showed ICI, like the PherDal kit offers, and IUI have the same live birth rate over a 6 month time period in medicated and natural ovulation cycles (source). Similar results were found in a 2018 study (source). 


However, we believe our ICI kit is the first to combine the sterile environment of the fertility clinic with the at home capabilities of artificial insemination.  When it comes to the importance of sterile environments for infertility treatments, a 2017 study showed that women diagnosed with idiopathic (or unknown) infertility were proven to have a significant differentiation in the proportion of 3 bacterial species naturally present in the vaginal microbiome (source, source). Since then, there has continued to be more scientific research published about the role the microbiome plays in infertility. So much so that a 2020 review of clinical practice recommendations for fertility specialists called the vaginal microbiome the “new frontier” that would increase the overall knowledge of reproductive health (source).


Therefore, we believe we’re bridging the gap between traditional conception and more invasive options with a sterile ICI option for couples facing infertility, including male factor infertility, single mothers by choice, and the LGBTQ+ community. 


*The above is an image of a  proof of concept kit. Final future product is still currently under development and is not yet available on the market.



The Solution


Safe, sterile, at-home fertility option for everyone


We are looking to make safe and sterile at-home insemination possible. That’s why PherDal at-home insemination kits are designed to be able to deliver the sperm closer to the egg, potentially bypassing any bacterial or anatomical interference.


(source, source, source, source, source, source, source, source) 


We feel that PherDal is leading the industry by including 3 sterile syringes and 3 cups, per kit. That means more chances per month at less cost -  without reusing anything.


We feel our business model is similar to at-home, over-the-counter, pregnancy tests.  But what we think makes us unique is what we see as our unestablished market. We don’t think enough people know that sterile Intracervical insemination (ICI) is an option to try before Intrauterine insemination (IUI) - as a safe, affordable, way to try and build families.


(source)



The Market


The fertility treatment market is growing 


The Fertility Treatment Market size is valued at $14.27 billion in 2020 and is expected to reach $21.7 billion by 2025 (source).


Not to mention, almost two-thirds (64%) of couples trying to get pregnant have tried alternative or natural remedies to conceive (source).


We have found a new  industry containing an estimated 12.2 million people struggling to conceive each year (source). PherDal has the potential to offer these people a method of artificial insemination option that we feel is safe, sterile, and private - and we think we are the only ones doing so. 


(source, source, source, source, source) *The above is an image of a proof of concept kit. Final future product is still currently under development and is not yet available on the market.




Our Traction


PherDal's conception and progress

Here’s our timeline of how our founders overcame unexplained infertility, and how PherDal helped: 



While PherDal started as the founder’s story, our proof of concept kit launched last year - selling out in 90 days. Most importantly, we believe PherDal helped others successfully conceive too. We have now set a goal to be the only FDA-cleared insemination kit offered over-the-counter as a safe and sterile fertility option. 



Why Invest


We intend to offer the first over the counter assisted reproduction catheter to the growing  infertility space


And to us, success is giving people the potential to feel hope on their fertility journey. 


In the next 3-5 years, we anticipate PherDal being available in local pharmacies across North America and Europe - potentially providing a safe, sterile option for everyone.


We have already engaged with the United States FDA to initiate the premarket submission process. And with that, we anticipate having PherDal cleared via 510(k) premarket notification by the end of 2022.


Once manufacturing is scaled, we anticipate our PherDal kits to sell for less than $149 with a direct-to-consumer unit gross margin of in excess of 75%. 


We believe our patent is on track to be awarded this fall, putting us in the position, we feel, to potentially disrupt the 2023 market with our anticipated, patented, FDA-cleared, OTC medical device. 


(source, source, source, source, source, source, source, source)


*The above is an image of a proof of concept kit. Final future product is still currently under development and is not yet available on the market



ABOUT

HEADQUARTERS
405 W 2ND ST UNIT 1141
DIXON, IL 61021
WEBSITE
View Site
We believe PherDal is the only sterile, patent-pending, at-home insemination kit out there. Our goal is to provide access to safe and affordable fertility options backed by science. While we are pre-revenue, we have established the trademark for “Pherdal” and our proof-of-concept kits sold out in just 90 days and helped others conceive. We anticipate having a product on the market by the end of 2022.

TERMS

Overview
PRICE PER SHARE
DEADLINE
Jun. 8, 2025 at 5:23 PM UTC
VALUATION
Breakdown
MIN INVESTMENT
MAX INVESTMENT
OFFERING TYPE

Maximum Number of Shares Offered subject to adjustment for bonus shares

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

ALL UPDATES

01.31.24

📣 PherDal receives FDA CLEARANCE 📣

Dear PherDal Investors, 

You did it! Because of your unwavering support and contributions, 

PherDal has just received FDA clearance as the first and only sterile, over-the-counter, at-home insemination kit! 

And because of your generosity, millions of people now have access to the PherDal Kit, the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination. Thank you, from the bottom of our hearts.

 With news of FDA clearance, we can start accepting pre-orders of the Kit that will be shipped first come, first serve starting at the end of February.  While awaiting FDA clearance, we were unable to sell or re-stock our Kits. Now our team is working hard to make the PherDal Kit available as quickly as possible.  

Please follow and share our amazing news with everyone you know - 1 in 6 people in the world are impacted by infertility, many of whom struggle in silence.  They deserve to know that help is now available, thanks to your support!

Thank you for believing in PherDal and, most importantly, for giving millions of people hope. 

With deepest gratitude,

Dr. Jennifer Hintzsche and the PherDal team

Dear PherDal Investors,  You did it! Because of your unwavering support and contributions, PherDal has just received FDA clearance as the first and only sterile, over-the-counter, at–home insemination kit! And because of your generosity, millions of people now have access to the PherDal Kit, the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination. Thank you, from the bottom of our hearts. With news of FDA clearance, we are able to start accepting pre-orders of the Kit. While awaiting FDA clearance, we were unable to sell or re-stock our Kits. Now our team is working hard to make the PherDal Kit available as quickly as possible.  We’re also working to launch an affiliate program, for which you will be the first to be invited to join as a small token of our sincere gratitude for your support to get us here. Thank you for believing in PherDal and, most importantly, for giving millions of people hope. We will be back in touch again soon with more updates. In the meantime, we are wishing you and yours a wonderful holiday season. With deepest gratitude,Dr. Jennifer Hintzsche and the PherDal team

01.29.24

Fox News Feature

FDA approves first at-home sterile insemination kit to help with infertility: 'Gives me goosebumps'

Special thank you to Fox News for featuring an exclusive story about our historic FDA clearance news!


Here's an excerpt: 

Kits are shipping in February and can be pre-ordered at PherDal.com

We are so grateful to our investors and families for helping us achieve this historic success! 

-Dr. Jenn

09.08.23

PherDal Q2 Investor Update

Dear Investors, 

It is with immense gratitude that I share the latest strides and developments from the past quarter at PherDal. Here's a comprehensive overview of our Q2 accomplishments:

Quarterly Sales and Expenses:

I am thrilled to announce that, thanks to your unwavering support, we have successfully covered all costs related to our FDA clearance testing. Your commitment has been instrumental in propelling us forward. Moreover, we have proudly unveiled two impactful products aimed at supporting individuals on their journey to conceive. Our eBook, “Empower Your Fertility: Clear Steps Toward Conception”, has been met with enthusiasm. Additionally, we are excited to introduce the limited-time opportunity for 1:1 fertility consulting sessions with the renowned Dr. Jenn.

Team Update:

Dr. Jenn's exceptional contributions have not gone unnoticed. Her participation in the prestigious SXSW Pitch Competition as a finalist in the MedTech category is a testament to her innovation and expertise. Furthermore, Dr. Jenn was invited as a featured innovator at the Life Science Intelligence USA conference, underscoring her leadership in the field.

Dr. Jenn and PherDal have also been featured in reputable media outlets, including:

Industry Update:

We believe in collective vigilance to ensure our emerging industry’s compliance. We urge your assistance in identifying companies that may not be adhering to FDA regulations in women's health. If you suspect unlawful sales of medical devices on the internet without FDA clearance, please submit an anonymous report to the FDA using this link. Your contribution will play a vital role in safeguarding women's health.

Future Plans:

As we embrace the next quarter, our focus remains resolute. We are eagerly awaiting the results from the FDA clearance testing laboratories, a pivotal step toward realizing our vision. Upon obtaining these results, we are determined to submit them to the FDA, a milestone that will pave the way for obtaining clearance for the first-ever assisted reproduction kit offered over the counter, fortified by our patented sterile technology.

Feedback / Intros from Investors:

We continue to seek additional funding avenues to support our product launch and scale production capacity. If you are aware of any interested parties, please don't hesitate to contact investors@pherdal.com. 

We also love to connect with each of you and your network too! We would love introductions to be emailed to Support@PherDal.com to you or people you know that can help us in the following areas:  

  • Contribute to our successful product launch!
    • Distribution channels, funding opportunities, & marketing opportunities
  • Opportunities for media & press coverage of our story & our product launch!
  • Awareness-building initiatives & speaking opportunities for Dr. Jenn to share her story!

Your enduring support fuels our passion and perseverance. Together, we are making a profound impact in the realm of fertility solutions. If you have any insights, feedback, or suggestions, please feel free to reach out.

Warm regards,

Dr. Jenn


Dr. Jennifer Hintzsche, Ph.D.

CEO & Founder

PherDal Fertility Science, Inc.

12.19.22

PherDal's Campaign ends today.

This is it. 

We've given it our all. 

Thank you for the support investors we can't wait to make you proud.  


12.19.22

PherDal - 24 hours - INVESTMENT OPPORTUNITY ENDING

This is the last chance!

This won't happen again. 

Invest before it's gone. 

12.17.22

PherDal is almost done - 48 HOURS AND IT'S GONE!

INVEST NOW!

12.16.22

Don’t miss this - 3 Days left! Over $500K Invested!

Thank you for helping us hit $500K! This is the last 3 days before our campaign is over.

INVEST NOW! 

12.15.22

Announcing PherDal Baby #27!! 4 Days left!


OMGOODNESS ❤️ My heart is exploding!! 


I just learned about baby number 27 ❤️!! I can't tell you how much it means to me that these families share their stories and journey with me!


From the new mama: 

"I wanted to reach out and add a baby to the list! We purchased two Pherdal kits-one in November 2021 and the other in December 2021. We found out we were pregnant in January of this year, and our baby boy was born in September. We are so grateful for your product. I hadn’t even known about it as an option and thought we would have to have expensive and lengthy IUI or IVF procedures. Thanks to google, I found Pherdal and figured we had nothing to lose and tried it. I’m so thankful Pherdal existed at that time because it worked for us! Also, I really appreciated that there were three syringes per kit and that there was information/support included via downloadable guides as well. It made the whole process easier and less stressful for us!"



We need your help to give even more families this same beautiful gift. Invest now!! 

12.14.22

PherDal is officially PATENTED! 🥳 5 Days to go!

Last week Dr. Jenn received the official letter 

that PherDal is PATENTED!! 

Invest in our PATENTED medical device today!

12.13.22

Molly Hopkins shares PherDal's Story - 6 Days left



Thank you Molly Hopkins of LiviRae Lingerie & 90 Day Fiance for sharing our message!

INVEST NOW! 

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign reward.

@ 2025 All Rights Reserved

Apple App Store Badge
Google Play Store Badge

Get To Know Us

Our Team

Careers

Blog

Let's Work Together

Raise Capital

Refer a Founder, earn $10k

Success Stories

Partnerships

Need Help

Contact Us

Help Center

Terms of Use

Privacy Policy

Disclaimer

Annual Reports

Form CRS

Reg. BI Disclosure

Terms of Use

Privacy Policy

Disclaimer

Annual Reports

Form CRS

Reg. BI Disclosure

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.